Opthea announced that it has received a $6.3M research and development tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2021/2022 financial year, and represents the amount disclosed in the company’s audited financial statements at 30 June 2022.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OPT:
- Opthea Receives A$8.7 million R&D Tax Incentive
- Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference
- Opthea announces publication of Phase 2b trial results of OPT-302
- Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
- Opthea To Present at SVB Leerink Global Biopharma Conference